GlobalData: Herpes Simplex - Pipeline Assessment and Market Forecasts to 2017 on reports-research.com

GlobalData, the industry analysis specialist’s new report, Herpes Simplex - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global herpes simplex market.

The report identifies the key trends shaping and driving the global herpes simplex market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global herpes simplex sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

The Herpes Simplex Therapeutics Market is Forecast to Show Modest Growth until 2017

The global herpes simplex therapeutics market was worth approximately $2.9 billion in 2009. In 2001 the market was valued at approximately $1 billion and it grew at an approximate Compound Annual Growth Rate (CAGR) of 13.9% from 2001 to 2009. The global herpes simplex therapeutics market is expected to reach $7.3 billion by 2017, after growing at a CAGR of 12.3% from 2009. The primary factor contributing to the increase in revenues over the forecast period is the increase in disease incidence. Presently, the therapeutic regimen for herpes simplex is dominated by a range of DNA polymerase inhibitors which include Zovirax, Famvir, Valtrex, Denavir and OTC (Over-the-Counter) products such as Abreva and Aviralex. This market is a significantly genericized market, with many brands across the seven geographies covered in this report. Tablet prices range between $1 and $3 depending on the brand. The average annual cost of therapy for herpes simplex therapeutics ranges between $725 and $2,050 based on the treatment regimen (reduction or suppression therapy).

The Herpes Simplex Therapeutics Market Pipeline is Relatively Weak

The market has limited scope for growth due to the presence of generic products and the lack of innovation with respect to better efficacy and safety drug profiles. The herpes simplex developmental pipeline is weak, with only 34 molecules in the various phases of clinical development. There are five first-in-class molecules across all the phases of development. Overall, there are eight molecules whose mechanisms of action are not known or have not been disclosed by the parent company. Phase III contains no first-in-class molecules but has five generic candidates. Phase II contains only one first-in-class molecule, which is a helicase-primase inhibitor.

The Herpes Simplex Therapeutics Market Has Low Unmet Needs to be Addressed

The herpes simplex therapeutics market has moderate to low unmet needs in terms of both efficacy and safety. The low unmet needs imply that the market is well served by the current product options and that there is not much scope available for new entrants to capture value from underserved segments. The efficacy of the present therapeutics ranges from moderate to strong, with drugs such as Zovirax having significantly strong efficacy profiles. The therapeutic interventions for herpes simplex are limited to oral formulations. Since the market is genericized, there are many available brands and prices are low.
Safety is a moderate concern for this market. The occurrence of headaches and nausea is prevalent among the patient population and safer drugs are needed. Apart from these complications, dizziness and abdominal pain also make up a major share of the side effects for the present therapeutics drugs. The need for safer drugs, especially with respect to the target population of patients between the ages of 18 and 50 years, is the primary unmet need for the herpes simplex therapeutics market.

The Reluctance to Seek Treatment is a Major Barrier to the Herpes Simplex Therapeutics Market

Herpes Simplex virus infections are a significant health issue with a considerable social and economic impact. Patients’ Quality of Life (QOL) can be significantly impacted by this disorder as psychological, occupational, social domestic, physical, and sexual functioning are all affected.
Even though there are a significant number of therapeutic options in the market, herpes simplex remains under-recognized and untreated due to patients’ embarrassment and reluctance to seek medical help. This lack of awareness and reluctance to seek treatment affects the herpes simplex therapeutics market considerably.

GlobalData: Herpes Simplex - Pipeline Assessment and Market Forecasts to 2017:
http://www.reports-research.com/studien/herpes-simplex-pipeline-assessment-market-forecasts-2017-p-108611.html

GlobalData: More market data and market reports:
http://www.reports-research.com/studien/globaldata-m-304.html

markt-studie.de, founded in 2002 has emerged as a leading online portal for market surveys and market research in German speaking areas. Four years later the English language portal reports-research.com was introduced due to the extraordinary success of the portal. Again one year later estudio-mercado.es - the Spanish spoken portal - was founded. The objective of the three portals is to competently and efficiently support consultants and decision makers in management, sales and marketing in the search for worldwide market research. Prospective buyers can look into more than 60,000 market surveys from more than 200 international publishers, current market data for more than 6,000 branches worldwide, 10,000 company profiles as well as a free-of-charge research and recommendation service for individual market research.

reports-research.com
c/o dynamic technologies GmbH
Siegburger Str. 233
50679 Köln
Germany

Manuel Bravo Sanchez (CEO)

info@reports-research.com
or
Tel ++49 (0)221 677 897 32
Fax ++49 (0)221 677 897 34

This release was published on openPR.